Traditional screening for cervical cancer-a pap smear followed by microscopic examination of the cervix-often gives false positives that force needless, painful, and costly biopsies. A new optical diagnostic device now being tested in large human trials could give more precise answers cheaply. And it could reach patients in two to three years.
The new technology is a pencil-sized probe that shines ultraviolet and visible light onto the cervix. Precancerous cells contain more mitochondria-the power plants of cells-which fluoresce when light of those wavelengths strikes them; so an increase in fluorescence means more precancerous cells. In a study of more than 100 women last year, researchers at the University of Texas at Austin and the M. D. Anderson Cancer Center in Houston, TX, found the method provided 50 percent fewer false-positive readings than standard methods. Now, two trials involving 1,800 women in Texas and Canada are under way, and the technology could be ready for the U.S. Food and Drug Administration’s approval process next year, says Michele Follen, an oncologist at M. D. Anderson. “Physicians could screen, diagnose, and make decisions about treatment all in one shot,” says Rebecca Richards-Kortum, a biomedical engineer at the University of Texas and one of the probe’s developers. That would be particularly welcome in developing countries, where most of the world’s 300,000 annual cervical-cancer deaths occur, and where today’s testing methods are unavailable or beyond the means of most women. In the U.S., Follen estimates, widespread adoption could save more than $600 million a year in health-care costs.
Other groups are using infrared light to check for breast cancer. At some wavelengths, infrared light can penetrate several centimeters into the body and is sensitive to changes in blood oxygen content and blood volume, which correlate with tumor growth. “In a few years, radiologists are going to be able to press a button and get optical information to complement mammography,” says Bruce Tromberg, a biomedical engineer developing an optical breast-cancer screening test at the University of California, Irvine. Using light also avoids the need for radiation, says Daniel Sullivan, head of the cancer imaging program at the National Cancer Institute in Bethesda, MD. He cautions that optical imaging won’t replace existing methods but could complement them to improve accuracy and reduce needless biopsies.
|Michael Feld, MIT||Light probe for oral-, cervical-, and esophageal-cancer screening; now in human testing|
|Nimmi Ramanujam, |
University of Wisconsin-Madison
|Optical fiber threaded through biopsy needle to guide breast biopsy; in human trials|
|Rebecca Richards-Kortum, |
University of Texas at Austin
|Ultraviolet- and visible-light-emitting device for cervical-cancer screening; regulatory filing could come as early as next year|
|Bruce Tromberg, |
University of California, Irvine
|Handheld infrared device for breast cancer screening; could enter large-scale human testing in three years|
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.